Geode Capital Management’s Kaival Brands Innovations Group KAVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-42,905
Closed -$18.4K 4521
2025
Q3
$18.4K Buy
42,905
+1,005
+2% +$630 ﹤0.01% 4420
2025
Q2
$20.7K Sell
41,900
-579
-1% -$313 ﹤0.01% 4357
2025
Q1
$23.4K Buy
42,479
+23,009
+118% +$21.8K ﹤0.01% 4321
2024
Q4
$17.8K Buy
19,470
+6,089
+46% +$5.37K ﹤0.01% 4397
2024
Q3
$15K Buy
+13,381
New +$12.5K ﹤0.01% 4430
2024
Q1
Sell
-6,489
Closed -$27.4K 4623
2023
Q4
$27.4K Hold
6,489
﹤0.01% 4463
2023
Q3
$57.5K Buy
6,489
+528
+9% +$6.61K ﹤0.01% 4389
2023
Q2
$98.3K Hold
5,961
﹤0.01% 4339
2023
Q1
$90.1K Hold
5,961
﹤0.01% 4380
2022
Q4
$112K Sell
5,961
-14
-0.2% -$310 ﹤0.01% 4355
2022
Q3
$126K Hold
5,975
﹤0.01% 4452
2022
Q2
$198K Buy
5,975
+258
+5% +$7.04K ﹤0.01% 4275
2022
Q1
$170K Buy
5,717
+4,236
+286% +$139K ﹤0.01% 4454
2021
Q4
$23K Sell
1,481
-925
-38% -$26K ﹤0.01% 4936
2021
Q3
$69K Buy
+2,406
New +$259K ﹤0.01% 4741

Geode Capital Management's KAVL Position: Q4 2025 in Review

Geode Capital Management sold out of Kaival Brands Innovations Group (KAVL) in Q4 2025, closing a stake of 42,905 shares — an estimated $18.4K sold.

Geode Capital Management first reported a position in KAVL in Q3 2021 and held it in 15 quarters. The position peaked at $198K in Q2 2022. 0 funds tracked by Wall St. Rank hold KAVL as of Q4 2025.

  • Geode Capital Management reported no remaining Kaival Brands Innovations Group position as of Q4 2025 after selling out during the quarter.
  • Geode Capital Management sold 42,905 Kaival Brands Innovations Group shares in Q4 2025, an estimated $18.4K.
  • Geode Capital Management first reported a position in Kaival Brands Innovations Group in Q3 2021 and held it in 15 quarters.
  • Geode Capital Management's Kaival Brands Innovations Group position peaked at $198K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Kaival Brands Innovations Group as of Q4 2025.

Based on Geode Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.